OncRef

Clinical Trial: NCT04296162

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Fudan University
Information Provided By:Fudan University
Last Update Posted:2026-05-26

Study Overview

Brief Summary

This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node negative, HER-2 positive and small tumor size breast cancer

Official Title

A Phase II Study to Assess the Effectiveness and Safety of Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: Vinorelbine
  • Drug: Capecitabine
  • Drug: Trastuzumab

Other Study ID Numbers

  • 1503144-7

Start Date (Actual)

2020-03-10

Primary Completion Date (Actual)

2026-04-25

Study Completion Date (Actual)

2026-04-25

Enrollment (Actual)

182

Study Type

Interventional

Phase

Phase 2